Categories: News

WSPN Launches White-Label Stablecoin Infrastructure to Enable Enterprises to Issue Branded Stablecoins

TORTOLA, British Virgin Islands, Dec. 5, 2025 /PRNewswire/ — Worldwide Stablecoin Payment Network (WSPN), a leading provider of next-generation stablecoin infrastructure, today announced the launch of its White-Label Stablecoin Solution, enabling enterprises and financial institutions to rapidly deploy their own branded stablecoins using WSPN’s production-grade infrastructure.

- Advertisement -

The offering leverages WSPN’s proven stablecoin technology stack, which already powers WUSD in live production. By providing a turnkey solution, WSPN eliminates the technical complexity and regulatory burden traditionally associated with launching a stablecoin.

- Advertisement -

“Building a scalable stablecoin from scratch requires significant engineering resources, regulatory expertise, and operational infrastructure,” said Raymond Yuan, Founder & CEO of WSPN. “Our White-Label Solution allows enterprises to launch their own branded stablecoins in a fraction of the time and cost, backed by the same infrastructure that powers our own tokens.”

- Advertisement -

The solution includes four core components: client-controlled mint and burn smart contracts/infrastructure, custody and wallet infrastructure, KYT compliance layer for regulatory adherence, and user front-end with APIs for seamless integration.

- Advertisement -

WSPN is already powering a euro-denominated stablecoin for an EU-based partner and is actively onboarding additional clients across multiple jurisdictions and currency denominations. The solution is designed for financial institutions, payment providers, and enterprises seeking to leverage stablecoin technology without building infrastructure from the ground up.

- Advertisement -

For more information, contact WSPN’s business development team or visit www.wspn.io

- Advertisement -

About WSPN

- Advertisement -

WSPN is a leading provider of next-generation stablecoin infrastructure, dedicated to building a more secure, efficient, and transparent global payment ecosystem. Our flagship stablecoin, WUSD, is fully backed and pegged 1:1 to the U.S. Dollar, serving as the foundation for a suite of integrated financial solutions. These solutions support a range of financial applications from institutional treasury management to programmable payments and decentralized finance. With a strong focus on transparency, regulatory compliance, and user accessibility, WSPN bridges the gap between Web3 innovation and traditional financial systems, driving the global adoption of stablecoins at scale.

- Advertisement -

Learn more: www.wspn.ioX | LinkedIn

- Advertisement -

Logo – https://mma.prnewswire.com/media/2429245/WSPN_logo_Logo.jpg

- Advertisement -

View original content:https://www.prnewswire.co.uk/news-releases/wspn-launches-white-label-stablecoin-infrastructure-to-enable-enterprises-to-issue-branded-stablecoins-302633900.html

- Advertisement -

Recent Posts

Crypto News: AlphaPepe Presale Records Surge in Whale Accumulation As Bitcoin Price Prediction Eyes $180,000

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto news is turning toward AlphaPepe after the…

8 hours ago

Crypto Market News: AlphaPepe Finalizes Tier-1 Exchange Shortlist as XRP Price Prediction Targets $5.00

MONACO, May 16, 2026 (GLOBE NEWSWIRE) -- Crypto market news is turning toward AlphaPepe after…

8 hours ago

Qoder Version 1.0 Released: Full Automation of Code Generation, Verification & Delivery

SINGAPORE, May 16, 2026 (GLOBE NEWSWIRE) -- Qoder officially releases version 1.0, upgrading from an…

8 hours ago

Ipsen presents first-in-class late-breaking Phase II corabotase data in glabellar lines showing sustained duration of effect reinforced by consistently high patient satisfaction

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placeboAt Week 24, 60.8% of patients treated with corabotase experienced clinically…

8 hours ago

ImPact Biotech Presents Updated Data from Phase 3 ENLIGHTED Trial of Padeliporfin VTP in LG-UTUC at AUA 2026

– Complete response (CR) observed in 70% (50/72) of evaluable patients with low-grade upper tract…

8 hours ago

Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers

- Stenoparib clinical development continues in relapsed small cell lung cancer and, under FDA Fast…

8 hours ago